2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults14 5. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/ AHA Guideline for the Management of ST-Elevation Myocardial 6. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease16 7. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure17 Statements/Performance Measures 1. 2015 ACC/AHA Focused Update of Secondary Prevention Lipid 2. Third Universal Definition of Myocardial Infarction8 3. ACC/AHA 2008 Performance Measures for Adults With ST- Elevation and Non ST-Elevation Myocardial Infarction2 4. ACC/AHA 2008 Statement on Performance Measurement and ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; ESC indicates European Society of Cardiology; HFSA, Heart Failure Society of America; and SCAI, Society for Cardiovascular Angiography and Interventions. 6 number of reasons (eg, concerns about its bleeding risk). In this case, the provider would receive credit for the measure. However, if the patient had explicitly expressed to the pro- vider that he/she did not wish to have the medication pre- scribed, no prescription will be written and the provider can then document in the medical record patient s refusal of the medication. In this scenario, the provider will not be penal- ized for this performance measure because a valid patient reason is documented. The writing committee closely delib- erated the exceptions to be included with each measure and, in some cases, determined not to include any exceptions (as in the case of the patient safety measures). 